Betta Pharmaceuticals Co., Ltd.

SZSE:300558 Stock Report

Market Cap: CN¥19.3b

Betta Pharmaceuticals Valuation

Is 300558 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300558 (CN¥46.95) is trading below our estimate of fair value (CN¥161.07)

Significantly Below Fair Value: 300558 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300558?

Key metric: As 300558 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300558. This is calculated by dividing 300558's market cap by their current earnings.
What is 300558's PE Ratio?
PE Ratio42.8x
EarningsCN¥459.57m
Market CapCN¥19.25b

Price to Earnings Ratio vs Peers

How does 300558's PE Ratio compare to its peers?

The above table shows the PE ratio for 300558 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.2x
000739 Apeloa PharmaceuticalLtd
17.5x17.9%CN¥18.7b
002773 Chengdu Kanghong Pharmaceutical Group
14.9x13.4%CN¥17.7b
600329 Tianjin Pharmaceutical Da Ren Tang Group
27.8x20.8%CN¥22.4b
600062 China Resources Double-Crane PharmaceuticalLtd
16.5x16.6%CN¥21.9b
300558 Betta Pharmaceuticals
42.8x26.7%CN¥19.3b

Price-To-Earnings vs Peers: 300558 is expensive based on its Price-To-Earnings Ratio (42.8x) compared to the peer average (19.2x).

Price to Earnings Ratio vs Industry

How does 300558's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300558 42.8xIndustry Avg. 29.2xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300558 is expensive based on its Price-To-Earnings Ratio (42.8x) compared to the CN Pharmaceuticals industry average (29.2x).

Price to Earnings Ratio vs Fair Ratio

What is 300558's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300558 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.8x
Fair PE Ratio31.5x

Price-To-Earnings vs Fair Ratio: 300558 is expensive based on its Price-To-Earnings Ratio (42.8x) compared to the estimated Fair Price-To-Earnings Ratio (31.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300558 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥46.95
CN¥50.70
+8.0%
18.3%CN¥60.00CN¥41.40n/a2
Nov ’25CN¥45.66
CN¥50.70
+11.0%
18.3%CN¥60.00CN¥41.40n/a2
Oct ’25CN¥45.97
CN¥50.10
+9.0%
19.8%CN¥60.00CN¥40.20n/a2
Sep ’25CN¥35.50
CN¥50.10
+41.1%
19.8%CN¥60.00CN¥40.20n/a2
Aug ’25CN¥34.49
CN¥50.98
+47.8%
17.7%CN¥60.00CN¥41.95n/a2
Jul ’25CN¥33.65
CN¥50.98
+51.5%
17.7%CN¥60.00CN¥41.95n/a2
Jun ’25CN¥37.82
CN¥50.98
+34.8%
17.7%CN¥60.00CN¥41.95n/a2
May ’25CN¥41.73
CN¥50.98
+22.2%
17.7%CN¥60.00CN¥41.95n/a2
Apr ’25CN¥41.72
CN¥57.03
+36.7%
14.0%CN¥65.00CN¥49.06n/a2
Mar ’25CN¥43.59
CN¥57.03
+30.8%
14.0%CN¥65.00CN¥49.06n/a2
Feb ’25CN¥37.30
CN¥57.03
+52.9%
14.0%CN¥65.00CN¥49.06n/a2
Jan ’25CN¥51.55
CN¥58.25
+13.0%
11.6%CN¥65.00CN¥51.49n/a2
Dec ’24CN¥56.39
CN¥58.25
+3.3%
11.6%CN¥65.00CN¥51.49n/a2
Nov ’24CN¥61.65
CN¥58.25
-5.5%
11.6%CN¥65.00CN¥51.49CN¥45.662
Oct ’24CN¥57.28
CN¥57.04
-0.4%
14.0%CN¥65.00CN¥49.08CN¥45.972
Sep ’24CN¥49.66
CN¥57.04
+14.9%
14.0%CN¥65.00CN¥49.08CN¥35.502
Aug ’24CN¥52.50
CN¥67.80
+29.1%
25.4%CN¥85.00CN¥50.59CN¥34.492
Jul ’24CN¥48.03
CN¥67.80
+41.2%
25.4%CN¥85.00CN¥50.59CN¥33.652
Jun ’24CN¥55.88
CN¥67.80
+21.3%
25.4%CN¥85.00CN¥50.59CN¥37.822

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.85

7D

-10.1%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥37.2b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.97

7D

-1.7%

1Y

17.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.9b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.29

7D

-0.7%

1Y

16.7%